The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
The European Commission approves belantamab mafodotin for the treatment of patients with RRMM
On August 26, 2020, the European Commission granted a conditional marketing authorization to belantamab mafodotin, a first-in-class humanized anti-B-cell maturation antigen (BCMA) monotherapy, for the treatment of adult patients with relapsed/refractory multiple myeloma (RRMM) who have previously received at least four therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and experienced disease progression on the last treatment.1
The approval was based on the results from the DREAMM-2 trial (NCT03525678), which demonstrated that belantamab mafodotin monotherapy, administered as a 2.5 mg/kg dose every 3 weeks, resulted in an overall response rate of 32% in patients with RRMM. In the 13-month follow-up period, the median duration of response was 11 months, and the median overall survival was 13.7 months.
Overall, belantamab mafodotin was safe and tolerable. The most frequently reported adverse events in the 2.5 mg/kg arm were keratopathy (71%), thrombocytopenia (38%), anemia (27%), blurred vision events (25%), nausea (25%), and pyrexia (23%).
Earlier this month, the U.S. Food and Drug Administration (FDA) granted approval to belantamab mafodotin monotherapy in the same setting; click here for the update, which includes the Society for Immunotherapy of Cancer (SITC) recommendations for the use of belantamab mafodotin.
Click here to read the full prescribing information of belantamab mafodotin (for use in the U.S.).
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content